Home/Filings/4/0000950170-25-004548
4//SEC Filing

Jacobs Bruce N. 4

Accession 0000950170-25-004548

CIK 0001815442other

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 7:00 AM ET

Size

7.0 KB

Accession

0000950170-25-004548

Insider Transaction Report

Form 4
Period: 2025-01-10
Jacobs Bruce N.
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-10$2.08/sh+10,000$20,800178,921 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-01-1010,00094,899 total
    Exercise: $2.08Exp: 2029-08-28Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]This number includes 367 shares acquired under the Registrant's employee stock purchase plan on December 1, 2024
  • [F2]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares vested in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Documents

1 file

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother

Related Parties

1
  • filerCIK 0001821074

Filing Metadata

Form type
4
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 7:00 AM ET
Size
7.0 KB